Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
RASAGILINETARTRAAT 1,4 mg/stuk SAMENSTELLING overeenkomend met ; RASAGILINE 1 mg/stuk
DOC Generici S.r.l. Via Filippo Turati 40 20121 MILANO (ITALIË)
N04BD02
RASAGILINETARTRAAT 1,4 mg/stuk SAMENSTELLING overeenkomend met ; RASAGILINE 1 mg/stuk
Tablet
CELLULOSE, MICROKRISTALLIJN (E 460(i)) ; MAÏSZETMEEL ; MAÏSZETMEEL, GEPREGELATINEERD ; STEARINEZUUR (E 570) ; TALK (E 553 B) ; WIJNSTEENZUUR, (L (+) Vorm) (E 334), CELLULOSE, MICROKRISTALLIJN (E 460) ; MAÏSZETMEEL ; MAÏSZETMEEL, GEPREGELATINEERD ; STEARINEZUUR (E 570) ; TALK (E 553 B) ; WIJNSTEENZUUR, (L (+) Vorm) (E 334),
Oraal gebruik
Rasagiline
Hulpstoffen: CELLULOSE, MICROKRISTALLIJN (E 460); MAÏSZETMEEL; MAÏSZETMEEL, GEPREGELATINEERD; STEARINEZUUR (E 570); TALK (E 553 B); WIJNSTEENZUUR, (L (+) Vorm) (E 334);
2015-11-27
Page 1 of 7 Proposed var 05 PACKAGE LEAFLET: INFORMATION FOR THE USER RASAGILINE DOC GENERICI 1 MG, TABLETTEN Rasagiline READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Rasagiline DOC Generici is and what it is used for 2. What you need to know before you take Rasagiline DOC Generici 3. How to take Rasagiline DOC Generici 4. Possible side effects 5. How to store Rasagiline DOC Generici 6. Contents of the pack and other information 1 WHAT RASAGILINE DOC GENERICI IS AND WHAT IT IS USED FOR Rasagiline DOC Generici is used for the treatment of Parkinson’s disease in adults. It can be used together with or without Levodopa (another medicine that is used to treat Parkinson’s disease). With Parkinson’s disease, there is a loss of cells that produce dopamine in the brain. Dopamine is a chemical in the brain involved in movement control. Rasagiline DOC Generici helps to increase and sustain levels of dopamine in the brain. 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE RASAGILINE DOC GENERICI DO NOT TAKE RASAGILINE DOC GENERICI - if you are allergic to rasagiline or any of the other ingredients of this medicine (listed in section 6). - if you have severe liver problems. Do not take the following medicines while taking Rasagiline DOC Generici: - monoamine oxidase (MAO) inhibitors (e.g. for treatment of depression or Parkinson’s disease, or used for any other indication), including medicinal and natural products without prescription e.g. St. John's Wort. - pethidine (a strong pain killer). You must wait a Lees het volledige document
Nov 2015: MA in NL – Nov 2016: NL approval var 01 – Dec 2018: NL approval var02 – Mar 2020: NL approval of renewal application – Proposed var 05 1. NAME OF THE MEDICINAL PRODUCT Rasagiline DOC Generici 1 mg, tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 1 mg rasagiline (as tartrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet White to off-white, oblong (approximately 11.5 mm x 6 mm), biconvex tablets, debossed with ‘R9SE’ on one side and ‘1’ on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Rasagiline DOC Generici is indicated in adults for the treatment of idiopathic Parkinson’s disease as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose of rasagiline is 1 mg (one tablet of Rasagiline DOC Generici) once daily, to be taken with or without levodopa. _Elderly _ No change in dose is required for elderly patients (see section 5.2). _ _ _Hepatic impairment _ Rasagiline is contraindicated in patients with severe hepatic impairment (see section 4.3). Rasagiline use in patients with moderate hepatic impairment should be avoided. Caution should be used when initiating treatment with rasagiline in patients with mild hepatic impairment. In case patients progress from mild to moderate hepatic impairment rasagiline should be stopped (see section 4.4 and 5.2). _Renal impairment _ No special precautions are required in patients with renal impairment. _ _ _Paediatric population _ The safety and efficacy of Rasagiline DOC Generici in children and adolescents have not been established. There is no relevant use of Rasagiline DOC Generici in the paediatric population in the indication Parkinson’s disease. Method of administration Nov 2015: MA in NL – Nov 2016: NL approval var 01 – Dec 2018: NL approval var02 – Mar 2020: NL approval of renewal application – Proposed var 05 For oral use. R Lees het volledige document